2022
DOI: 10.1097/01.tp.0000886584.85217.46
|View full text |Cite
|
Sign up to set email alerts
|

315.3: Targeted Delivery of Galunisertib Attenuates Fibrogenesis in an Integrated Ex Vivo Renal Transplant and Fibrosis Model

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…We included kidneys that were enrolled in 13 different experiments having 37 experimental groups in total, of which data on nine studies have already been published. 18,22,[31][32][33][34][35][36][37][38][39][40][41] Of the excluded kidneys, the perfusate of 25 kidneys contained desmopressin or furosemide, while for another 57 kidneys, no data on hemoglobin level was available.…”
Section: Database Characteristicsmentioning
confidence: 99%
“…We included kidneys that were enrolled in 13 different experiments having 37 experimental groups in total, of which data on nine studies have already been published. 18,22,[31][32][33][34][35][36][37][38][39][40][41] Of the excluded kidneys, the perfusate of 25 kidneys contained desmopressin or furosemide, while for another 57 kidneys, no data on hemoglobin level was available.…”
Section: Database Characteristicsmentioning
confidence: 99%